Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs INO 1400 (Primary) ; INO 9012
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Inovio Pharmaceuticals
- 10 Nov 2017 Interim results presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017, according to an Inovio Pharmaceuticals media release.
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018, as reported by ClinicalTrials.gov.